Insilico Medicine and Inimmune Achieved collaboration to Revolutionize Immunotherapy with AI-Driven Drug Discovery
Cambridge, Mass, September 13, 2024 – Insilico Medicine(“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, today announced that the company has achieved a groundbreaking collaboration with Inimmune, which will utilize Chemistry42, Insilico’s proprietary generative artificial intelligence (AI) technology to accelerate the discovery and development of next-generation immunotherapeutics. Chemistry42, a multi-agent reinforcement learning system designed […]
